AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8751017 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release (CR) diltiazem, given twice a day (b.i.d.)
Number of subjects: 41
Study 8751017 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain diltiazem, given four times a day (q.i.d.)
Number of subjects: 41
Study 8751017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 8751017 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CR and plain diltiazem
Number of subjects: 41
Study 2225497 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium alginate haemostatic swabs
Number of subjects: 72
Study 2225497 — intervention group
Group type: COMPARATOR
Intervention: Normal gauze swabs
Number of subjects: 72
Study 367575 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl CCNU, 5-FU and Vincristine (MOF A)
Number of subjects: 67
Study 367575 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl CCNU, 5-FU and Vincristine (MOF B)
Number of subjects: 67
Study 31672329 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAAem supplementation
Number of subjects: 155
Study 31672329 — intervention group
Group type: COMPARATOR
Intervention: Diet advice (Control)
Number of subjects: 155
Study 30857647 — intervention group
Group type: EXPERIMENTAL
Intervention: Veverimer 6 g/day
Number of subjects: 217
Study 30857647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study 27661788 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered methadone treatment (PCM; n = 149)
Number of subjects: 300
Study 27661788 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU; n = 151)
Number of subjects: 300
Study 25385260 — intervention group
Group type: EXPERIMENTAL
Intervention: Decernotinib 25 mg
Number of subjects: 204
Study 25385260 — intervention group
Group type: EXPERIMENTAL
Intervention: Decernotinib 50 mg
Number of subjects: 204
Study 25385260 — intervention group
Group type: EXPERIMENTAL
Intervention: Decernotinib 100 mg
Number of subjects: 204
Study 25385260 — intervention group
Group type: EXPERIMENTAL
Intervention: Decernotinib 150 mg
Number of subjects: 204
Study 25385260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 24093324 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (aspirin and clopidogrel)
Number of subjects: 80
Study 24093324 — intervention group
Group type: COMPARATOR
Intervention: Aspirin and placebo
Number of subjects: 80
Study 21854643 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured medication assessment including withdrawal of fall-risk increasing drugs
Number of subjects: 0
Study 21854643 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 0
Study 19383161 — intervention group
Group type: EXPERIMENTAL
Intervention: Accurate++ probe
Number of subjects: 20
Study 19383161 — intervention group
Group type: COMPARATOR
Intervention: Coach probe
Number of subjects: 20
Study 17279301 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐mmx5‐mm pieces of latex‐free rubber
Number of subjects: 44
Study 17279301 — intervention group
Group type: EXPERIMENTAL
Intervention: 12‐mmx1.5‐mm metallic bowel clips
Number of subjects: 44
Study 17279301 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall markers (both types)
Number of subjects: 44
Study 17279301 — intervention group
Group type: EXPERIMENTAL
Intervention: Cecal intubation
Number of subjects: 44
Study 17279301 — intervention group
Group type: EXPERIMENTAL
Intervention: Insertion and withdrawal times
Number of subjects: 44
Study 17279301 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection rates by endoscopists
Number of subjects: 44
Study 17279301 — intervention group
Group type: EXPERIMENTAL
Intervention: Markers placed at flexures
Number of subjects: 44
Study 15491246 — intervention group
Group type: EXPERIMENTAL
Intervention: nefazodone + GC
Number of subjects: 242
Study 15491246 — intervention group
Group type: EXPERIMENTAL
Intervention: nefazodone + CBT
Number of subjects: 242
Study 15491246 — intervention group
Group type: COMPARATOR
Intervention: placebo + CBT
Number of subjects: 242
Study 15491246 — intervention group
Group type: COMPARATOR
Intervention: placebo + GC
Number of subjects: 242
Study 11830755 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptastigmine
Number of subjects: 1500
Study 11830755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1500
Study 9621140 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg once daily for 3 months followed by itraconazole 200 mg once weekly for 3 months (ITR-ITR group)
Number of subjects: 1608
Study 9621140 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg once daily for 3 months followed by oral placebo once weekly for 3 months (ITR-PLAC group)
Number of subjects: 1608
Study 9621140 — intervention group
Group type: COMPARATOR
Intervention: Miconazole cream twice daily for 6 months (MIC-MIC group)
Number of subjects: 1608
Study 8173149 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 30 mg q12h
Number of subjects: 607
Study 8173149 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg qd
Number of subjects: 607
Study 8173149 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin 5000 units q8h
Number of subjects: 607
Study 8173149 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin groups (30 mg and 40 mg)
Number of subjects: 607
Study 30706733 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervene video
Number of subjects: 1243
Study 30706733 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1243
Study 29116826 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS with adjustment of pulse amplitude
Number of subjects: 21
Study 29116826 — intervention group
Group type: COMPARATOR
Intervention: TENS without adjustment of pulse amplitude
Number of subjects: 21
Study 27431049 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine linkage (induction, stabilization, bridge prescription, and facilitated referral to outpatient treatment)
Number of subjects: 113
Study 27431049 — intervention group
Group type: COMPARATOR
Intervention: Detoxification (5-day inpatient buprenorphine taper)
Number of subjects: 113
Study 27431049 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine linkage
Number of subjects: 113
Study 27431049 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-buprenorphine days
Number of subjects: 113
Study 24933451 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavior therapy (ICBT), 7-10 weekly modules guided by online therapists
Number of subjects: 100
Study 24933451 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavior therapy (ICBT)
Number of subjects: 100
Study 22870676 — intervention group
Group type: EXPERIMENTAL
Intervention: Pizhen treatment
Number of subjects: 85
Study 22870676 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular injection with sodium hyaluronate (Control)
Number of subjects: 85
Study 22870676 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Pizhen and Control
Number of subjects: 85
Study 20207411 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory intervention with women's groups
Number of subjects: 19030
Study 20207411 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 19030
Study 19465145 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) plus behavior therapy
Number of subjects: 109
Study 19465145 — intervention group
Group type: COMPARATOR
Intervention: Behavior therapy only (Control)
Number of subjects: 109
Study 16553955 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate blood test ordering (Group 1)
Number of subjects: 0
Study 16553955 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting policy (Group 2)
Number of subjects: 0
Study 16553955 — intervention group
Group type: COMPARATOR
Intervention: Postponement of testing with quality improvement strategy (Group 3)
Number of subjects: 0
Study 15223858 — intervention group
Group type: EXPERIMENTAL
Intervention: Doubling the dose (DD) of inhaled corticosteroid
Number of subjects: 290
Study 15223858 — intervention group
Group type: COMPARATOR
Intervention: Maintenance dose (MD) of inhaled corticosteroid
Number of subjects: 290
Study 11205650 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard education plus computer‐assisted instruction (CAI)
Number of subjects: 86
Study 11205650 — intervention group
Group type: COMPARATOR
Intervention: Standard education
Number of subjects: 86
Study 11248878 — intervention group
Group type: EXPERIMENTAL
Intervention: Interesterified fat blend
Number of subjects: 60
Study 11248878 — intervention group
Group type: COMPARATOR
Intervention: Non-interesterified fat blend
Number of subjects: 60
Study 8279255 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-hour fasting interval after ingestion of apple juice (10 ml/kg b.w.)
Number of subjects: 105
Study 8279255 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-hour fasting interval after ingestion of apple juice (10 ml/kg b.w.)
Number of subjects: 105
Study 8279255 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-hour fasting interval after ingestion of apple juice (10 ml/kg b.w.)
Number of subjects: 105
Study 8279255 — intervention group
Group type: COMPARATOR
Intervention: Control group (2-hour fasting interval)
Number of subjects: 105
Study 2886997 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluperlapine (NB‐106‐689)
Number of subjects: 26
Study 2886997 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 26
Study 31648815 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 3 g per day for 5 days before and 21 days after surgery
Number of subjects: 61
Study 31648815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 29114733 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium oxybate (3.0 to 9.0 g per night for 6 weeks)
Number of subjects: 12
Study 29114733 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium oxybate
Number of subjects: 12
Study 29114733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 27064832 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 73
Study 27064832 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 73
Study 24953067 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% chlorhexidine gluconate
Number of subjects: 80
Study 24953067 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% povidone‐iodine
Number of subjects: 80
Study 24953067 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol‐based hand rub
Number of subjects: 80
Study 24953067 — intervention group
Group type: COMPARATOR
Intervention: Plain soap and water
Number of subjects: 80
Study 23185261 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosamax (Alendronate Sodium)
Number of subjects: 76
Study 23185261 — intervention group
Group type: COMPARATOR
Intervention: Immunosuppressive agents
Number of subjects: 76
Study 21086869 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartCode BLS with voice assisted manikin (VAM)
Number of subjects: 603
Study 21086869 — intervention group
Group type: COMPARATOR
Intervention: Standard instructor-led (IL) course with regular manikins
Number of subjects: 603
Study 18698047 — intervention group
Group type: EXPERIMENTAL
Intervention: gp100(209-2M) immunization
Number of subjects: 0
Study 15774213 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 200 mg/d
Number of subjects: 138
Study 15774213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 12695266 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin(s)
Number of subjects: 0
Study 12695266 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran (direct thrombin inhibitor)
Number of subjects: 0
Study 12695266 — intervention group
Group type: EXPERIMENTAL
Intervention: Nematode anticoagulant peptide c2 (tissue factor VIIa inhibitor)
Number of subjects: 0
Study 12695266 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium N-[8(2-hydroxylbenzoyl)amino] caprylate (SNAC)/heparin (heparin derivative)
Number of subjects: 0
Study 12695266 — intervention group
Group type: EXPERIMENTAL
Intervention: Danaparoid sodium (heparinoid)
Number of subjects: 0
Study 12695266 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux (selective factor Xa inhibitor)
Number of subjects: 0
Study 10323374 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg DHEA for 3 months
Number of subjects: 39
Study 10323374 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 39
Study 8630575 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg zileuton, a 5-lipoxygenase inhibitor
Number of subjects: 24
Study 8630575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 2006743 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 mL water
Number of subjects: 30
Study 2006743 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 mL coffee
Number of subjects: 30
Study 2006743 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 mL pulp-free orange juice
Number of subjects: 30
Study 7129722 — intervention group
Group type: EXPERIMENTAL
Intervention: 10:20 regimen (35 10‐s maximal isometric contractions separated by a 20‐s rest)
Number of subjects: 11
Study 7129722 — intervention group
Group type: EXPERIMENTAL
Intervention: 10:5 regimen (35 maximal isometric contractions separated by 5 s between trials)
Number of subjects: 11
Study 31760820 — intervention group
Group type: EXPERIMENTAL
Intervention: CPVI started with right pulmonary veins at RAGP site (group A)
Number of subjects: 80
Study 31760820 — intervention group
Group type: COMPARATOR
Intervention: CPVI started with left pulmonary veins first, last ablation site is RAGP (group B)
Number of subjects: 80
Study 31760820 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 80
Study 28961737 — intervention group
Group type: EXPERIMENTAL
Intervention: Miltefosine monotherapy
Number of subjects: 95
Study 28961737 — intervention group
Group type: COMPARATOR
Intervention: Miltefosine combination therapy
Number of subjects: 95
Study 25428627 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% lidocaine patches
Number of subjects: 36
Study 25428627 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 36
Study 25141535 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated and co-contraction training of trunk stabilizers
Number of subjects: 0
Study 25141535 — intervention group
Group type: COMPARATOR
Intervention: Control group (resting comfortably on a chair)
Number of subjects: 0
Study 21934585 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Compression Device (MCD)
Number of subjects: 395
Study 21934585 — intervention group
Group type: COMPARATOR
Intervention: Low-Molecular-Weight Heparin (LMWH)
Number of subjects: 395
Study 19377147 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) distraction technique provided through a cell phone connected to an HMD
Number of subjects: 0
Study 19377147 — intervention group
Group type: COMPARATOR
Intervention: No-distraction control condition
Number of subjects: 0
Study 17410417 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral opioid blockade
Number of subjects: 145
Study 17410417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 15704589 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuesaitong Injection, i.v., once a day for 14 days
Number of subjects: 86
Study 15704589 — intervention group
Group type: COMPARATOR
Intervention: Routine therapy with western medicine (Control)
Number of subjects: 86
Study 15704589 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuesaitong Injection
Number of subjects: 86
Study 11437674 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 1500
Study 11437674 — intervention group
Group type: COMPARATOR
Intervention: Standard immunosuppressive protocols (cyclosporin and corticosteroids)
Number of subjects: 1500
Study 9257765 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 250 mg administered at 1000 hours
Number of subjects: 12
Study 9257765 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 250 mg administered at 2200 hours
Number of subjects: 12
Study 7693424 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 30 mg/day orally for 3 years (Group A, n = 192)
Number of subjects: 741
Study 7693424 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC 50 for 6 cycles (Group B, n = 183)
Number of subjects: 741
Study 7693424 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 30 mg/day orally for 3 years plus FEC 50 for 6 cycles (Group C, n = 182)
Number of subjects: 741
Study 7693424 — intervention group
Group type: COMPARATOR
Intervention: No medical adjuvant treatment (Group D, n = 184)
Number of subjects: 741
Study 3121334 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA + heparin
Number of subjects: 68
Study 3121334 — intervention group
Group type: COMPARATOR
Intervention: placebo + heparin
Number of subjects: 68
Study 30904867 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother and Baby Units (MBUs)
Number of subjects: 0
Study 30904867 — intervention group
Group type: COMPARATOR
Intervention: Generic acute psychiatric wards
Number of subjects: 0
Study 30904867 — intervention group
Group type: COMPARATOR
Intervention: Crisis Resolution Teams (CRTs)
Number of subjects: 0
Study 28636851 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg IV every 2 weeks)
Number of subjects: 423
Study 28636851 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (platinum-based, administered once every 3 weeks for up to six cycles)
Number of subjects: 423
Study 28636851 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 423
Study 28636851 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 423
Study 26289514 — intervention group
Group type: EXPERIMENTAL
Intervention: Hibiscus sabdariffa (HS)
Number of subjects: 80
Study 26289514 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 80
Study 26289514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 23432779 — intervention group
Group type: EXPERIMENTAL
Intervention: Dressing removed on postoperative day one
Number of subjects: 200
Study 23432779 — intervention group
Group type: COMPARATOR
Intervention: Dressing removed on postoperative day six
Number of subjects: 200
Study 20336685 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal exercise protocol
Number of subjects: 10
Study 20336685 — intervention group
Group type: COMPARATOR
Intervention: Control condition (nonthermal exercise)
Number of subjects: 10
Study 20374312 — intervention group
Group type: COMPARATOR
Intervention: CLAs 2.5 g
Number of subjects: 87
Study 20374312 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E 400 mg
Number of subjects: 87
Study 20374312 — intervention group
Group type: COMPARATOR
Intervention: CLAs and Vitamin E
Number of subjects: 87
Study 20374312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 17598577 — intervention group
Group type: EXPERIMENTAL
Intervention: Active eye-tracking on (n = 25)
Number of subjects: 50
Study 17598577 — intervention group
Group type: COMPARATOR
Intervention: Active eye-tracking off (n = 25)
Number of subjects: 50
Study 15107507 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate
Number of subjects: 80
Study 15107507 — intervention group
Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 80
Study 12204708 — intervention group
Group type: EXPERIMENTAL
Intervention: latanoprost 0.005% in the evening
Number of subjects: 2
Study 12204708 — intervention group
Group type: COMPARATOR
Intervention: timolol 0.5% twice daily
Number of subjects: 2
Study 12204708 — intervention group
Group type: EXPERIMENTAL
Intervention: latanoprost 0.005% adjunctively
Number of subjects: 2
Study 9612832 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured advice from physician and referral to individual behavior change counseling during prenatal care
Number of subjects: 0
Study 9612832 — intervention group
Group type: COMPARATOR
Intervention: Brief advice to stop smoking and a quit smoking booklet at first visit (usual care)
Number of subjects: 0
Study 7924168 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (1g/kg body weight)
Number of subjects: 12
Study 7924168 — intervention group
Group type: COMPARATOR
Intervention: Juice (control)
Number of subjects: 12
Study 2571386 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphasalazine (SAS)
Number of subjects: 28
Study 2571386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 53370 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-A polysaccharide vaccine
Number of subjects: 16458
Study 53370 — intervention group
Group type: COMPARATOR
Intervention: Control (not vaccinated)
Number of subjects: 16458
Study 31365184 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD patients
Number of subjects: 152
Study 31365184 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 152
Study 27761791 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (L. acidophilus, L. rhamnosus, and L. sporogenes)
Number of subjects: 50
Study 27761791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 25879008 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 2 mg/kg (group A)
Number of subjects: 32
Study 25879008 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 4 mg/kg (group B)
Number of subjects: 32
Study 25879008 — intervention group
Group type: COMPARATOR
Intervention: Sugammadex 2 mg/kg (group A) and Sugammadex 4 mg/kg (group B)
Number of subjects: 32
Study 23444169 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal-Naproxen fixed-dose combination (FDC) tablet
Number of subjects: 24
Study 23444169 — intervention group
Group type: COMPARATOR
Intervention: Co-administration of two separate diflunisal and naproxen marketed tablets
Number of subjects: 24
Study 21120461 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin 1000 mg/day for 2 days, followed by 2000 mg/day for 5 days
Number of subjects: 18
Study 21120461 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe/simvastatin 10 mg/20 mg/day
Number of subjects: 18
Study 21120461 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of extended-release niacin and ezetimibe/simvastatin
Number of subjects: 18